CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-1004 will be featured in an oral presentation and a poster presentation at the upcoming Muscular Dystrophy Association Scientific Conference. The Muscular Dystrophy Association Scientific Conference will be held March 11-14, 2015, in Washington, DC.
Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will
give a presentation titled “CAT-1004, a Novel Anti-Inflammatory Agent
in Development for the Treatment of Duchenne Muscular Dystrophy (DMD):
Design of a Phase 1/2 Study”
- The oral presentation will take place during the Clinical Trials session on Saturday, March 14, 2015, from 10:30am to 11:00am ET in the Thurgood Marshall Ballroom
- The poster will be presented on Thursday, March 12, 2015, from 6:00pm to 8:00pm ET in Exhibit Call C
CAT-1004 is a new chemical entity that inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays an important role in muscle health. In skeletal muscle, activated NF-kB drives muscle degeneration and suppresses muscle regeneration. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase 1 clinical trials, CAT-1004 inhibited NF-kB and was well tolerated with no observed safety concerns. Catabasis Pharmaceuticals plans to initiate a Phase 1/2 clinical trial of CAT-1004 for the treatment of DMD in the first half of 2015.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s initial focus is on treatments for orphan diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.